USA - NASDAQ:ASLN - US04522R2004 - ADR
ChartMill assigns a Buy % Consensus number of 83% to ASLN. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-14 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-31 | Roth MKM | Initiate | Buy |
| 2023-04-28 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-27 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-20 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-27 | Piper Sandler | Maintains | Overweight |
| 2023-02-27 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-16 | Piper Sandler | Maintains | Overweight |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2021-07-09 | Jefferies | Initiate | Buy |
| 2021-03-17 | HC Wainwright & Co. | Maintains | Buy |
8 analysts have analysed ASLN and the average price target is 77.52 USD. This implies a price increase of 12820% is expected in the next year compared to the current price of 0.6.
The consensus rating for ASLAN Pharmaceuticals Ltd (ASLN) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.